Study guide
13.3 Anticoagulants and Antiplatelets: The SDCEP Protocol
Overseas Registration Examination ORE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: ORE Part 1 — Exam Blueprint, Logistics and Strategy
1.1 Structure and Format of ORE Part 1 1.2 The Official Blueprint and Preparing for Practice 1.3 Eligibility, Fees, Attempts and Time Limits
2 Chapter 2: Anatomy of the Head and Neck
2.1 The Trigeminal Nerve and Dental Innervation 2.2 The Facial Nerve and Parotid Region 2.3 The Temporomandibular Joint and Muscles of Mastication 2.4 The Infratemporal Fossa and Spread of Odontogenic Infection
3 Chapter 3: Dental Anatomy, Morphology and Occlusion
3.1 Permanent and Primary Tooth Morphology 3.2 Functional Occlusion: Centric Relation, Guidance and Interferences 3.3 Classifying Occlusion: Angle and BSI Incisor Relationships
4 Chapter 4: Genetics, Embryology and Odontogenesis
4.1 Stages of Odontogenesis and Molecular Signalling 4.2 Amelogenesis and Enamel Microstructure 4.3 Dentinogenesis and the Pulp-Dentine Complex 4.4 Cementum, the Periodontal Ligament and Oral Mucosa 4.5 Genetic and Developmental Dental Anomalies
5 Chapter 5: Oral Biology and Salivary Physiology
5.1 Salivary Gland Anatomy, Microarchitecture and Innervation 5.2 Salivary Secretion, Flow Rates and Autonomic Control 5.3 Salivary Buffering Systems and Protective Macromolecules 5.4 Physiology of Mastication and Deglutition 5.5 Taste, Lingual Papillae and Gustatory Pathways 5.6 Xerostomia, Sjogren's Syndrome and Salivary Diagnostics
6 Chapter 6: Physiology of the Major Body Systems
6.1 Cardiovascular and Respiratory Physiology 6.2 Renal, Endocrine and Gastrointestinal Physiology 6.3 Haematology and Haemostasis 6.4 Neurophysiology, Pain and the Autonomic Nervous System
7 Chapter 7: Bone Biology, Calcium Homeostasis and Healing
7.1 Microstructure and Architecture of Alveolar Bone 7.2 Bone Remodelling and the RANK/RANKL/OPG Axis 7.3 Endocrine Control of Calcium and Phosphate 7.4 Extraction Socket Healing and Ridge Resorption 7.5 Impaired Healing: MRONJ, Osteoradionecrosis and Systemic Risk
8 Chapter 8: Oral Microbiology and Biofilm Ecology
8.1 The Oral Microbiome and Biofilm Development 8.2 Cariogenic Microbiology: Mutans Streptococci and Lactobacilli 8.3 Ecological Hypotheses of Dental Caries 8.4 Biofilm Tolerance and the Case for Mechanical Plaque Control
9 Chapter 9: Immunology Relevant to Oral Disease
9.1 Innate Mucosal Immunity and Gingival Crevicular Fluid 9.2 Cellular Immunity in the Periodontium 9.3 Microbial Pathogenesis: Complexes and Keystone Pathogens 9.4 Host-Mediated Tissue Destruction 9.5 Hypersensitivity Reactions in Dental Practice 9.6 Autoimmune Mucocutaneous Bullous Disease 9.7 Immunodeficiency and Oral HIV Manifestations
10 Chapter 10: General Pathology and Neoplasia
10.1 Cellular Adaptation and Mechanisms of Cell Death 10.2 Inflammation, Wound Healing and Repair 10.3 Principles of Neoplasia and Carcinogenesis 10.4 TNM Staging of Oral Cavity Carcinoma
11 Chapter 11: Statistics and Research Methods
11.1 Study Designs and the Hierarchy of Evidence 11.2 Descriptive and Inferential Statistics 11.3 Diagnostic Test Performance 11.4 Critical Appraisal, Bias and Research Governance
12 Chapter 12: Human Disease: Cardiovascular and Respiratory
12.1 Infective Endocarditis and NICE CG64 12.2 Hypertension and Blood Pressure Thresholds for Dental Care 12.3 Angina, Myocardial Infarction and Antiplatelet Therapy 12.4 Asthma, COPD and Respiratory Emergencies
13 Chapter 13: Human Disease: Endocrine, Haematological and Renal
13.1 Diabetes Mellitus and the Periodontal Axis 13.2 Congenital Bleeding and Clotting Disorders 13.3 Anticoagulants and Antiplatelets: The SDCEP Protocol 13.4 Chronic Kidney Disease and Haemodialysis
14 Chapter 14: Human Disease: Gastrointestinal, Hepatic and Neurological
14.1 Gastrointestinal Disease and Intrinsic Dental Erosion 14.2 Liver Disease, Coagulopathy and Viral Hepatitis 14.3 Epilepsy, Stroke and Transient Ischaemic Attack 14.4 Trigeminal Neuralgia, Bell's Palsy and Giant Cell Arteritis
15 Chapter 15: Oral Aspects of Human Disease
15.1 Oral Manifestations of Systemic Disease 15.2 Orofacial Pain and Temporomandibular Disorders 15.3 Dry Mouth, Altered Taste and Halitosis
16 Chapter 16: Infection Prevention and Control
16.1 The Decontamination Cycle, Sterilization and Waterlines 16.2 Routes of Transmission and Blood-Borne Viruses
17 Chapter 17: Dental Materials
17.1 Dental Amalgam: Metallurgy and UK Regulation 17.2 Resin Composites: Chemistry and Placement 17.3 Dental Adhesive Systems 17.4 Acid Etching, the Hybrid Layer and MMP Degradation 17.5 Glass Ionomer Cements, RMGICs and Compomers 17.6 Impression Materials and Digital Scanning 17.7 Luting Cements and Adhesive Conditioning Protocols 17.8 Dental Ceramics and Cast Alloys 17.9 Gypsum Products, Waxes and Denture Base Polymers
18 Chapter 18: Behavioural Sciences Relevant to Oral Health Care
18.1 Health Behaviour Models and Behaviour Change 18.2 Dental Anxiety and Phobia 18.3 Psychosocial and Sociological Determinants of Oral Health
19 Chapter 19: Patient Assessment and Diagnosis
19.1 History Taking and Clinical Examination 19.2 Special Investigations and Reaching a Diagnosis
20 Chapter 20: Treatment Planning and Risk-Based Care
20.1 Treatment Planning and Sequencing 20.2 Risk Assessment, Recall Intervals and Preventive Planning
21 Chapter 21: Cariology and Caries Risk Assessment
21.1 Caries Pathogenesis and the Stephan Curve 21.2 Histopathology of Enamel and Dentinal Caries 21.3 Caries Diagnosis, ICDAS and Risk Assessment
22 Chapter 22: Operative Dentistry and Minimal Intervention
22.1 Minimal Intervention and Selective Caries Removal 22.2 Pulp Vitality Assessment and Biological Pulp Capping 22.3 Cavity Design, the C-Factor and Margin Geometry
23 Chapter 23: Endodontics
23.1 Pulp Histology and the Low-Compliance Environment 23.2 Pulpal Neurophysiology and Dentine Hypersensitivity 23.3 Pulpal and Periapical Diagnostic Terminology 23.4 Endodontic Diagnostic Testing 23.5 Access Cavity Design and Canal Configurations 23.6 Working Length Determination and Canal Preparation 23.7 Chemical Disinfection and Irrigant Activation 23.8 Medicaments, Obturation Materials and Techniques 23.9 Restoring Endodontically Treated Teeth 23.10 Endodontic Emergencies, Cracked Teeth and Root Fracture
24 Chapter 24: Periodontology
24.1 The 2018 Classification and Periodontal Health 24.2 Plaque-Induced and Non-Plaque-Induced Gingival Disease 24.3 Staging and Grading Periodontitis 24.4 Peri-Implant Disease and Systemic Risk Factors 24.5 The Basic Periodontal Examination 24.6 Simplified BPE in Children and Full Periodontal Charting 24.7 Furcation Involvement, Mobility and Occlusal Trauma 24.8 The BSP Stepwise Treatment Framework 24.9 Periodontal Instrumentation and Healing 24.10 Re-Evaluation, Endpoints and Periodontal Surgery 24.11 Crown Lengthening, Supracrestal Attachment and Supportive Care
25 Chapter 25: Fixed Prosthodontics
25.1 Biomechanical Principles of Tooth Preparation 25.2 Margin Design and the Supracrestal Attachment 25.3 Bridge Design and Resin-Bonded Bridges 25.4 Gingival Retraction, Provisionals and Temporary Cements
26 Chapter 26: Removable Prosthodontics
26.1 Removable Partial Dentures: Classification, Design and Surveying 26.2 Complete Dentures: Principles, Impressions and Jaw Registration
27 Chapter 27: Paediatric Dentistry
27.1 Primary Tooth Anatomy and Caries Management Strategies 27.2 Preformed Metal Crowns and the Hall Technique 27.3 Pulp Therapy in Primary Teeth 27.4 Extractions in the Primary Dentition 27.5 Non-Pharmacological Behaviour Management 27.6 Inhalation Sedation in Paediatric Dentistry 27.7 The Developing Dentition and Space Management 27.8 Serial Extraction and Non-Nutritive Sucking Habits
28 Chapter 28: Dental Traumatology
28.1 Trauma Assessment and Fractures of Permanent Teeth 28.2 Luxation Injuries, Avulsion and Replantation 28.3 Primary Tooth Trauma and Splinting Specifications
29 Chapter 29: Orthodontics
29.1 Extraoral Orthodontic Assessment 29.2 Intraoral Occlusal Assessment 29.3 Skeletal Pattern and Cephalometric Analysis 29.4 IOTN and NHS Treatment Eligibility 29.5 Upper Removable Appliances 29.6 Functional and Fixed Appliances 29.7 Biology of Orthodontic Tooth Movement 29.8 Orthodontic Risks and Retention
30 Chapter 30: Oral Surgery
30.1 Exodontia Biomechanics and Instrument Selection 30.2 Surgical Flap Design, Bone Removal and Suturing 30.3 Third Molar Surgery and NICE Guidance 30.4 Dry Socket and Oroantral Communication 30.5 Odontogenic Infection and Fascial Space Spread
31 Chapter 31: Oral Medicine
31.1 Recurrent Aphthous Stomatitis 31.2 Oral Candidiasis 31.3 Viral Oral Infections 31.4 Reactive Soft Tissue Lesions and the Epulides 31.5 Oral Potentially Malignant Disorders 31.6 Oral Squamous Cell Carcinoma, Urgent Referral and Biopsy
32 Chapter 32: Oral Pathology
32.1 Odontogenic and Non-Odontogenic Cysts 32.2 Odontogenic Tumours 32.3 Obstructive and Reactive Salivary Gland Disease 32.4 Salivary Gland Neoplasms
33 Chapter 33: Therapeutics and Prescribing
33.1 Local Anaesthetic Chemistry and Mechanism of Action 33.2 UK Local Anaesthetic Formulations 33.3 Vasoconstrictors, Maximum Doses and Systemic Toxicity 33.4 Analgesics for Acute Dental Pain 33.5 Antimicrobial Stewardship and First-Line Regimens 33.6 Antifungal and Antiviral Therapeutics
34 Chapter 34: Medical Emergencies in Dental Practice
34.1 The ABCDE Approach and the Emergency Drug Kit 34.2 Anaphylaxis and Acute Coronary Syndrome 34.3 Hypoglycaemia, Acute Asthma and Seizures 34.4 Syncope, Adrenal Crisis, Choking and Resuscitation
35 Chapter 35: Dental Radiology and Radiation Protection
35.1 Radiation Physics, Filtration and Collimation 35.2 Intraoral, Bitewing and Occlusal Projections 35.3 Dental Panoramic Tomography: Principles, Positioning and Errors 35.4 Lateral Cephalometry and Cone Beam CT 35.5 Systematic Reporting and Radiographic Caries Diagnosis 35.6 Radiology of Periodontal Bone Loss and Jaw Lesions 35.7 Radiographic Quality Assurance 35.8 IRR17 and IR(ME)R 2017
36 Chapter 36: Special Care Dentistry and Conscious Sedation
36.1 Special Care Dentistry, Risk Stratification and Sedation Principles 36.2 Inhalation Sedation with Nitrous Oxide 36.3 Intravenous Sedation with Midazolam 36.4 Oral Sedation and General Anaesthesia Referral
37 Chapter 37: Dental Public Health
37.1 Delivering Better Oral Health and the Fluoride Toolkit 37.2 Oral Health Epidemiology and Indices 37.3 Inequalities, Water Fluoridation and Population Prevention 37.4 NHS Dental Services, Access and Commissioning
38 Chapter 38: Communication and Interpersonal Skills
38.1 Patient Communication and Shared Decision-Making 38.2 Breaking Bad News, Complaints and the Duty of Candour 38.3 Referrals, Records and Communication with the Team
39 Chapter 39: Consent and Capacity
39.1 Valid Consent and the Montgomery Standard 39.2 The Mental Capacity Act 2005 39.3 Best Interests Decisions and Lasting Power of Attorney 39.4 Consent in Children and Young People 39.5 Safeguarding Children and Vulnerable Adults 39.6 Confidentiality, Data Protection and Lawful Disclosure
40 Chapter 40: Clinical Professionalism and the GDC
40.1 The General Dental Council and Standards Principles 1 to 4 40.2 GDC Standards: Principles 5 to 9 40.3 The GDC Fitness to Practise Process 40.4 Clinical Governance and the Audit Cycle
41 Chapter 41: Health and Safety Law in Dental Practice
41.1 Health and Safety Legislation, COSHH, RIDDOR and Sharps
42 Chapter 42: Self-Management and Professional Development
42.1 Enhanced CPD, Lifelong Learning and Reflective Practice 42.2 Managing Time, Stress and Clinical Wellbeing 42.3 Leadership, Delegation and Practice Management
13.3 Anticoagulants and Antiplatelets: The SDCEP Protocol
Key Takeaways Explain This Topic AI
The INR must be checked within 72 hours of an invasive procedure, or within 24 hours if the patient's control is unstable.
Invasive dental treatment may proceed when the INR is below 4.0 with local haemostatic measures; at 4.0 or above, defer and seek medical advice.
Warfarin should not be stopped for routine dental extractions; local measures are oxidised regenerated cellulose, resorbable sutures and 5% tranexamic acid.
For higher bleeding risk procedures SDCEP advises miss or delay the morning DOAC dose rather than stopping the drug for days.
Single antiplatelet therapy with aspirin or clopidogrel should be continued without interruption for dental procedures.
Last updated: September 2026
3. Anticoagulant and Antiplatelet Management: SDCEP Guidelines
In the UK, management of dental patients on antithrombotic medications is strictly governed by the evidence-based guidance of the Scottish Dental Clinical Effectiveness Programme (SDCEP: Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs) . Patient on Antithrombotic Therapy Requiring Extraction
- │
- ┌────────────────────────────────────┼────────────────────────────────────┐
- ▼ ▼ ▼
- Warfarin DOACs Antiplatelets
- (Vitamin K Antagonist) (Apixaban, Rivaroxaban, Dabigatran) (Aspirin, Clopidogrel)
- │ │ │
Check INR ≤ 72 hrs pre-op Low Bleeding Risk: Single Antiplatelet:
- │ Do NOT alter timing Do NOT stop
- ├── If INR < 4.0: │ │
│ PROCEED without Higher Bleeding Risk: Dual Antiplatelet (DAPT):
- │ stopping Warfarin • Once-daily: Delay AM dose NEVER stop without
- │ • Twice-daily: Omit AM dose Cardiologist OK
- └── If INR ≥ 4.0: • NO Heparin Bridging │
- DEFER & contact GP │ │
- └────────────────────────────────────┴────────────────────────────────────┘
- │
- ▼
Mandatory Local Haemostasis:
- Oxidized Cellulose (Surgicel) + Resorbable Sutures
- + Biting on 5% Tranexamic Acid Gauze (20 mins)
- Warfarin (Vitamin K Antagonist)
Warfarin inhibits the enzyme vitamin K epoxide reductase (VKORC1) , blocking the gamma-carboxylation of glutamic acid residues on vitamin K-dependent clotting factors (Factors II, VII, IX, and X) and regulatory proteins C and S. Therapy is monitored using the International Normalised Ratio (INR) , which standardises Prothrombin Time (PT).
The INR Check Timing: The patient's INR must be assessed within 72 hours prior to the procedure . If the patient has a history of an unstable INR, fluctuating diet, or concurrent antibiotic/antifungal therapy, the INR must be measured within 24 hours .
The Safe INR Threshold ( < 4.0 < 4.0 < 4.0 ): If the INR is < 4.0 < 4.0 < 4.0 , proceed with minor oral surgery (extractions of up to 3 teeth, subgingival scaling) WITHOUT interrupting or altering the warfarin dose . Discontinuing warfarin exposes the patient to an immediate, catastrophic risk of thromboembolic stroke, deep vein thrombosis, or mechanical prosthetic valve thrombosis—a clinical risk far exceeding the morbidity of localized post-operative socket oozing.
INR ≥ 4.0 \ge 4.0 ≥ 4.0 : Defer invasive dental care. Do not adjust the warfarin dose yourself; refer the patient to their anticoagulant clinic or general practitioner for dose titration.
Mandatory Local Haemostatic Measures:
Pack the extraction socket with oxidized regenerated cellulose (Surgicel) or resorbable collagen sponge.
Place interrupted resorbable sutures (e.g., 3-0 or 4-0 polyglactin 910 [Vicryl]) to approximate gingival wound edges under tension-free closure.
Instruct the patient to bite firmly on a sterile gauze pack soaked in 5% tranexamic acid solution for 20 minutes.
Advise the patient to avoid hot food/drinks, vigorous rinsing, or strenuous exercise for 24 hours, and prescribe paracetamol for analgesia (avoid NSAIDs and aspirin).
Direct Oral Anticoagulants (DOACs)
DOACs (also known as Non-Vitamin K Antagonist Oral Anticoagulants, NOACs) directly and selectively inhibit specific enzymes in the coagulation cascade. They exhibit rapid onset (1 to 3 hours), predictable pharmacokinetics, short elimination half-lives (10 to 14 hours in normal renal function), and do not require routine INR monitoring:
Direct Factor Xa Inhibitors: Apixaban (Eliquis) (twice daily), Rivaroxaban (Xarelto) (once daily), and Edoxaban (Lixiana) (once daily).
Direct Thrombin (Factor IIa) Inhibitor: Dabigatran etexilate (Pradaxa) (twice daily).
SDCEP Protocol for DOAC Management in Dental Surgery
Procedures with Low Risk of Bleeding (Simple extraction of 1 to 3 teeth, local scaling, restorations with subgingival margins):
Do NOT alter the DOAC dose or timing. Treat the patient at any time during the day and apply local haemostatic measures.
Procedures with Higher Risk of Bleeding (Extractions of ≥ 4 \ge 4 ≥ 4 teeth, surgical extractions with mucoperiosteal flaps, bone guttering, or gingival recontouring):
Once-Daily DOAC (taken in the morning, e.g., Rivaroxaban): Advise the patient to delay their morning dose on the day of surgery until after the procedure and haemostasis is confirmed, or take their normal dose in the evening.
Twice-Daily DOAC (e.g., Apixaban, Dabigatran): Advise the patient to omit the morning dose on the day of surgery. The normal evening dose is resumed that night, provided active bleeding has ceased.
Treat Early in the Day: Perform surgical procedures early in the morning so that any late secondary oozing can be addressed during working clinic hours.
No Heparin Bridging: Unlike warfarin in high-risk patients, DOACs never require bridging with low-molecular-weight heparin (LMWH) due to their rapid clearance and immediate therapeutic onset.
Antiplatelet Drugs (Aspirin, Clopidogrel, Ticagrelor)
Single Antiplatelet Therapy: Patients taking Aspirin (75 mg OD) or Clopidogrel (75 mg OD) as monotherapy should NOT stop their medication prior to dental extractions. Local haemostatic measures are entirely sufficient to achieve stable haemostasis.
Dual Antiplatelet Therapy (DAPT): Patients who have undergone coronary artery stent placement or acute coronary syndrome take Aspirin combined with Clopidogrel, Ticagrelor, or Prasugrel. DAPT must NEVER be stopped without direct consultation and approval from the patient's cardiologist. Abrupt cessation of DAPT precipitates acute coronary stent thrombosis and fatal myocardial infarction. Minor oral surgery can be safely executed on DAPT utilizing meticulous suturing, haemostatic socket packing, and pressure packs.
5. Clinical Traps, Worked Scenarios, and Practical Governance
Caution
Clinical Trap: Discontinuing Warfarin Prior to Minor Extractions: A dental practitioner instructs a patient with atrial fibrillation taking warfarin (current INR 2.8) to stop taking warfarin 3 days prior to an extraction to "prevent bleeding complications". Two days later, the patient suffers a massive ischaemic stroke secondary to left atrial thrombus embolisation. Under UK SDCEP guidelines, discontinuing warfarin with an INR < 4.0 < 4.0 < 4.0 for minor oral surgery is negligent clinical practice . The risk of thromboembolism far exceeds the risk of localized bleeding, which is easily controlled with sutures, Surgicel, and tranexamic acid gauze.
Warning
Clinical Trap: Cannulating the Arm with an Arteriovenous Fistula: A dental team treating an anxious dialysis patient under conscious sedation cannulates the cephalic vein in the patient's left forearm, ignoring a prominent surgical scar and a palpable vascular "thrill". The cannulation causes a massive haematoma, intraluminal thrombosis, and complete failure of the patient's radiocephalic (Brescia-Cimino) arteriovenous fistula. The patient requires emergency vascular surgery and temporary central venous catheterization with high infection risk. Always examine both arms before placing a blood pressure cuff or IV cannula in renal patients.
Worked Clinical SBA Scenario
Scenario: A 62-year-old male with a history of persistent non-valvular atrial fibrillation is taking Apixaban 5 mg twice daily . He presents to your dental clinic requiring a surgical extraction of tooth 36 involving root sectioning and a buccal mucoperiosteal flap. He has normal renal function. The procedure is scheduled for 09:30 AM.
Question: According to the Scottish Dental Clinical Effectiveness Programme (SDCEP) guidance, what is the exact advice regarding the patient's Apixaban regimen on the day of surgery, and what local haemostatic measures are mandatory?
Analysis and Clinical Governance: Surgical extraction involving a mucoperiosteal flap and bone removal is classified under SDCEP as an invasive procedure with a higher risk of bleeding . Because Apixaban is a twice-daily direct Factor Xa inhibitor with a peak plasma level occurring 1 to 3 hours post-ingestion, taking the morning dose prior to an 09:30 AM appointment would coincide surgery with peak anticoagulation. Under SDCEP guidance, the patient should be instructed to omit the morning dose of Apixaban on the day of surgery . The surgical procedure is performed in the morning. The socket is packed with oxidized regenerated cellulose (Surgicel) , closed with resorbable sutures , and the patient bites on 5% tranexamic acid-soaked gauze for 20 minutes. Once haemostasis is verified, the patient is instructed to resume their normal evening dose of Apixaban that night (at least 4 hours post-haemostasis). No heparin bridging is required.